Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2007 Sep;68(5):303–312. doi: 10.1016/j.curtheres.2007.10.003

Effects of Ondansetron and Granisetron on Postoperative Nausea and Vomiting in Adult Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Azize Bestas 1,a, Selami Ates Önal 1, Mustafa Kemal Bayar 1, Asli Yildirim 2, Erhan Aygen 3
PMCID: PMC3969949  PMID: 24692762

Abstract

Background: Postoperative nausea and vomiting (PONV) are common and potentially distressing adverse events (AEs) associated with surgery and anesthesia. In patients undergoing laparoscopic cholecystectomy (LC) without antiemetic prophylaxis, the incidence of PONV can be as high as 72%.

Objective: The aim of this study was to investigate the prophylactic antiemetic effects of ondansetron and granisetron in patients undergoing LC when these agents are administered before the end of surgery.

Methods: Patients classified by the American Society of Anesthesiologist's physical status as I or II who were scheduled for elective LC were included in this randomized, double-blind, placebo-controlled study. Anesthesia was induced with thiopental 5 mg/kg and fentanyl 2 μg/kg, and was maintained with isoflurane 1% to 3% in 50% oxygen and 50% nitrous oxide and fentanyl as needed. Approximately 20 to 30 minutes before the end of the surgery, the patients randomly received either IV ondansetron 100 μg/kg (group O), IV granisetron 40 μg/kg (group G), or normal saline (group P). Plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined preoperatively and 24 hours postoperatively. The patients were observed for 24 hours for PONV and other possible AEs. Postoperative pain intensity was determined using a 10-cm visual analogue scale. Four-point satisfaction scores were determined at 24 hours.

Results: Ninety patients (69 women, 21 men) participated in the study. Demographic characteristics and operative data (duration of surgery and anesthesia and amount of intraoperative fentanyl) were similar in the 3 groups. The only AE reported by patients during the 24-hour observation period was nonsevere headache. The number of patients experiencing headache was similar in group P, group O, and group G (10 [33%] patients, 6 [20%], and 10 [33%], respectively). No significant changes were found in presurgical and postsurgical plasma levels of ALT and AST in any group. The mean (SD) satisfaction scores in group O and group G (3.0 [0.4] and 3.0 [0.6], respectively) were significantly higher than those in group P (2.5 [0.5]; both, P < 0.01). Immediately after surgery (period 0), significantly more patients in the placebo group (21 [70%]) experienced PONV compared with those in the ondansetron group (9 [30%]; P < 0.05) and the granisetron group (7 [23%]; P < 0.01). During the 24-hour observation period, a significantly greater number of patients in group P (18 [60%]) required a single dose of a rescue antiemetic drug compared with those in groups O and G (9 [30%] and 6 [20%], respectively; both, P < 0.01).

Conclusions: Patients administered ondansetron 100 μg/kg or granisetron 40 μg/kg 20 to 30 minutes before the end of LC had significantly higher PONV control during the 24-hour postoperative observation period than patients receiving placebo. However, there were no significant differences between the active treatment groups in the incidence of PONV, patient satisfaction, or AEs.

Keywords: laparoscopic cholecystectomy, postoperative nausea and vomiting, ondansetron, granisetron

Full Text

The Full Text of this article is available as a PDF (605.1 KB).

References

  • 1.Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000;59:213–243. doi: 10.2165/00003495-200059020-00005. [DOI] [PubMed] [Google Scholar]
  • 2.Naguib M, El Bakry AK, Khoshim MH. Prophylactic antiemetic therapy withondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: A randomized, double-blind comparison with placebo. Can J Anaesth. 1996;43:226–231. doi: 10.1007/BF03011739. [DOI] [PubMed] [Google Scholar]
  • 3.Begos DG, Modlin IM. Laparoscopic cholecystectomy: From gimmick to gold standard. J Clin Gastroenterol. 1994;19:325–330. doi: 10.1097/00004836-199412000-00015. [DOI] [PubMed] [Google Scholar]
  • 4.Quaynor H, Raeder JC. Incidence and severity of postoperative nausea and vomiting are similar after metoclopramide 20 mg and ondansetron 8 mg given by the end of laparoscopic cholecystectomies. Acta Anaesthesiol Scand. 2002;46:109–113. [PubMed] [Google Scholar]
  • 5.Fujii Y, Tanaka H, Kawasaki T. A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: A double-blind, randomized, controlled trial. Clin Ther. 2003;25:1142–1149. doi: 10.1016/s0149-2918(03)80072-3. [DOI] [PubMed] [Google Scholar]
  • 6.Jellish WS, Thalji Z, Fluter E, Leonetti JR. Ondansetron versus droperidol or placebo when given prophylactically for the prevention of postoperative nausea and vomiting in patients undergoing middle ear procedures. J Clin Anesth. 1997;9:451–456. doi: 10.1016/s0952-8180(97)00099-8. [DOI] [PubMed] [Google Scholar]
  • 7.Taylor AM, Rosen M, Diemunsch PA. A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of postoperative nausea and vomiting in patients undergoing surgery with general anesthesia. J Clin Anesth. 1997;9:658–663. doi: 10.1016/s0952-8180(97)00190-6. [DOI] [PubMed] [Google Scholar]
  • 8.Kovac AL. Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Drug Saf. 2003;26:227–259. doi: 10.2165/00002018-200326040-00003. [DOI] [PubMed] [Google Scholar]
  • 9.Tang J, Wang B, White PF. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg. 1998;86:274–282. doi: 10.1097/00000539-199802000-00010. [DOI] [PubMed] [Google Scholar]
  • 10.Mikawa K, Takao Y, Nishina K. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Anesth Analg. 1995;80:970–974. doi: 10.1097/00000539-199505000-00020. [DOI] [PubMed] [Google Scholar]
  • 11.American Society of Anesthesiologists (ASA). ASA Physical Status Classification System [ASA Web site],; February 27, 2003. http://www.asahq.org/clinical/physicalstatus.htm Accessed.
  • 12.Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Effective dose of granisetron for the prevention of post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Eur J Anaesthesiol. 1998;15:287–291. [PubMed] [Google Scholar]
  • 13.Zarate E, Watcha MF, White PF. A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis. Anesth Analg. 2000;90:1352–1358. doi: 10.1097/00000539-200006000-00017. [DOI] [PubMed] [Google Scholar]
  • 14.So JB, Cheong KF, Sng C. Ondansetron in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: A prospective randomized study. Surg Endosc. 2002;16:286–288. doi: 10.1007/s00464-001-9036-3. [DOI] [PubMed] [Google Scholar]
  • 15.Milne RJ, Heel RC. Ondansetron Therapeutic use as an antiemetic. Drugs. 1991;41:574–595. doi: 10.2165/00003495-199141040-00006. [DOI] [PubMed] [Google Scholar]
  • 16.Kumakura H, Koyanagi J, Nishioka Y. Phase I study of granisetron (second report): Pharmacokinetics of granisetron following single and repeat intravenous drips infusion in Japanese healthy volunteers. J Clin Ther Med. 1990;6(Suppl 5):25–34. [Google Scholar]
  • 17.Kovac AL, O'Connor TA, Pearman MH. Efficacy of repeat intravenous dosing of ondansetron in controlling postoperative nausea and vomiting: A randomized, double-blind, placebo-controlled multicenter trial. J Clin Anesth. 1999;11:453–459. doi: 10.1016/s0952-8180(99)00067-7. [DOI] [PubMed] [Google Scholar]
  • 18.Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomized placebo-controlled trials. Anesthesiology. 1997;87:1277–1289. doi: 10.1097/00000542-199712000-00004. [DOI] [PubMed] [Google Scholar]
  • 19.Fujii Y, Tanaka H, Toyooka H. Effective dose of granisetron in the reduction of nausea and vomiting after breast surgery. Acta Anaesthsiol Scand. 1997;41:1167–1170. doi: 10.1111/j.1399-6576.1997.tb04860.x. [DOI] [PubMed] [Google Scholar]
  • 20.Fujii Y, Tanaka H, Toyooka H. Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting. Can J Anaesth. 1994;41:794–797. doi: 10.1007/BF03011585. [DOI] [PubMed] [Google Scholar]
  • 21.Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Prophylactic antiemetic therapy with granisetron in women undergoing thyroidectomy. Br J Anaesth. 1998;81:526–528. doi: 10.1093/bja/81.4.526. [DOI] [PubMed] [Google Scholar]
  • 22.Bhattacharya D, Banerjee A. Comparison of ondansetron and granisetron for prevention of nausea and vomiting following day care gynaecological laparoscopy. Indian J Anaesth. 2003;47:279–282. [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES